WEST CHESTER, Pa.--(BUSINESS WIRE)--Molecular Targeting Technologies, Inc. (MTTI) announced that Dr. Kai Chen of the University of Southern California was awarded the 2013 Center for Molecular Imaging Innovation and Translation (CMIIT) Young Investigator Award during the annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in Vancouver, Canada. Dr. Chen presented results from his study entitled: “Synthesis and evaluation of a novel bis (zinc(II)-dipicolyamine) derivative for dual-modality PET/NIRF imaging of phosphatidylserine exposure.”
This real time assessment probe can be used to monitor tumor response in as early as one day to evaluate treatment efficacy and intervene early in treatment modification. Non-invasive imaging of drug response has a significant clinical impact and can be broadly useful for monitoring numerous conditions, including cancer, cardiovascular diseases, neurology and renal diseases.
Dr. Kai Chen, Assistant Professor of the Department of Radiology at USC said, “Novel tools to assist in the non-invasive, real time assessment of tumor response to anti-cancer treatment are urgently needed. Our current preclinical results could lead to a robust imaging agent, offering synergistic advantages, not only to allow comprehensive collection of cell death information, but also to facilitate clinical applications of image-guided surgery.”
Chris Pak, President and CEO of MTTI said, “I want to congratulate Dr. Chen in winning this prestigious award. We envision this novel proprietary probe (MTTI-170) has the potential to provide early assessment of cancer treatment efficacy, leading to individually tailored therapeutic plans with improved patient outcomes.”
Molecular Imaging Center (MIC), University of Southern California (USC). The USC Molecular Imaging Center is located at the Keck School of Medicine’s Clinical Sciences Center. The center focuses on the translational needs of any investigator to allow in vivo imaging of disease processes and development of new molecular therapeutics and diagnostics. MIC’s mission is to provide scientists and physicians with state-of-the-art imaging technology for studying intact biological systems using a multimodality approach. Please visit the website: http://mic.usc.edu for more information.
Molecular Targeting Technologies, Inc. (MTTI). Molecular Targeting Technologies, Inc. is a privately held biotechnology company primarily focused on the identification, evaluation, acquisition and development of novel technologies for diagnosis and treatment of diseases. Please visit the website: www.mtarget.com for more information.